Canada: The Experimental Use Exception Under The Recently Amended Canadian Patent Act

Last Updated: September 26 2019
Article by David Schwartz and Aleksandra (Sasha) Gracia

Canada recently introduced new legislation (The Budget Implementation Act, 2018, No. 2) which brought about several changes to the Patent Act affecting the scope of protection available under Canadian patents. Included in the changes was the addition of a new provision providing an exception from infringement for experimental use of patented technologies.

New section 55.3 of the Patent Act, which came into force on December 13, 2018, provides:

55.3 (1) An act committed for the purpose of experimentation relating to the subject-matter of a patent is not an infringement of the patent.

(2) The Governor in Council may make regulations respecting

(a) factors that the court may consider, must consider or is not permitted to consider in determining whether an act is, or is not, committed for the purpose set out in subsection (1); and

(b) circumstances in which an act is, or is not, committed for the purpose set out in subsection (1).

The experimental use exception from infringement also extends to infringement of a Certificate of Supplementary Protection (CSP) issued for a patent.

The new provisions apply in respect of any action or proceeding that has not been finally disposed of as of December 13, 2018.

Prior Reference to Experimental Use in the Patent Act

Although there was no codified experimental use exception prior to these new provisions of the Act, a "Bolar" exception from infringement for activities occurring during the regulatory approval process is found in subsection 55.2(1), providing:

55.2(1) It is not an infringement of a patent for any person to make, construct, use or sell the patented invention solely for uses reasonably related to the development and submission of information required under any law of Canada, a province or a country other than Canada that regulates the manufacture, construction, use or sale of any product.

Notably, previous subsection 55.2(6) of the Act stated that the Bolar exception does not affect any exception from infringement for certain non-commercial or experimental use that might exist "at law":

55.2(6) For greater certainty, subsection (1) does not affect any exception to the exclusive property or privilege granted by a patent that exists at law in respect of acts done privately and on a non-commercial scale or for a non-commercial purpose or in respect of any use, manufacture, construction or sale of the patented invention solely for the purpose of experiments that relate to the subject-matter of the patent. (emphasis added)

With the enactment of section 55.3, subsection 55.2(6) has been amended to remove reference to experimental use, but the reference to non-commercial activity remains:

55.2(6) For greater certainty, subsection (1) does not affect any exception to the exclusive property or privilege granted by a patent that exists at law in respect of acts done privately and on a non-commercial scale or for a non-commercial purpose.

These related amendments may shed some light on the scope of new section 55.3, as they appear to emphasize a distinction between: (1) acts done privately and on a non-commercial scale or for a non-commercial purpose; and (2) use, manufacture, construction or sale of the patented invention solely for the purpose of experiments that relate to the subject-matter of the patent. This may suggest that the new exception from infringement could extend to experimental use that occurs in the commercial sphere.

History of the Experimental Use Exception in Canada

The seminal decision on the experimental use exception is that of the Supreme Court of Canada in Micro Chemicals v Smith Kline & French.1 This case involved Micro Chemicals performing a variety of experiments in preparation for obtaining a compulsory license from the patentee and a product made using the patented process before the grant of the license. The Supreme Court found Micro Chemicals' activities with respect to their preparation of experimental batches non-infringing, and held that the Trial Judge was incorrect to find otherwise, stating: "he was in error in holding as he did that an experimental user without a license in the course of bona fide experiments with a patented article is in law an infringer."2 The Court noted that the use was not for profit but to establish that Micro Chemicals could manufacture a quality product in accordance with the specification. Several factors were influential in the Court's decision:

  • The compound was produced in a small amount;
  • The compound was kept by Micro Chemicals and never entered into commerce;
  • No damage was suffered by the patentee;
  • No profits were made by Micro Chemicals relating to the activities; and
  • The activities were considered bona fide.

Canadian courts have also held that "testing" per se is not an infringing use.3

While the situation in Micro Chemicals was related to experimentation in preparation for a compulsory license, the principles therein are not limited to that situation. The experimental exception was revisited by the Federal Court of Appeal in Merck v Apotex, where it was held all that is required is that the infringing product was made merely by way of bona fide experiment, and not with the intention of selling and making use of the product in the commercial market.4 However, the Court did note that once the user has proceeded beyond the experimental and testing phase and has taken steps to manufacture, promote and sell the product, the experimentation exception no longer applies.5 In this case, the exception was held to be applicable to use of the patented product in ongoing research and development of alternate formulae, alternate techniques for tablet making, and the like.6

The limitation of the exception to non-commercial purposes was reinforced in Teva Canada Limited v Novartis AG, where it was held that the full inventory of the patented product that is made must be used for experimental or regulatory purposes and nothing is to be sold or used for commercial purposes.7

Thus, even in the absence of an experimental use exception in the Patent Act, Canadian courts have held that it is not an infringement to make or use a patented invention by way of experiment or testing only, without the intention of commercialization.8 Other cases that have been referenced by our courts indicate nor is it infringement to construct a patented article for the purpose of improving upon it or ascertaining whether a certain addition, subtraction, or improvement thereon is workable.9,10

Corresponding International Exceptions

Canada is not alone in enacting an exception from infringement for experimental use of a patented invention.

The national patent acts of many European Union (EU) member states contain research and experimental use exceptions from patent infringement, designed to allow for the promulgation of research activities to promote innovation.11 In Germany, a research privilege exists under §11 No.2 of the German Patent Act, whereby the effects of a patent shall not extend to "acts done for experimental purposes relating to the subject matter of the patented invention".12 Decisions of the German Federal Court of Justice have determined the scope and limitations of the experimental use exception, which is not only applicable to clinical trials, but also generally applicable to nonclinical research.13 The United Kingdom also has an experimental use provision/exception in §60(5)(b) of the United Kingdom Patent Act, which states that an act that would constitute an infringement of a patent for an invention shall not do so if it is done for experimental purposes relating to the subject matter of the invention.14 The UK courts have held that the experimental use exception covers activities that seek to generate genuinely new information but not those that seek to verify existing knowledge.15 Other EU member states with experimental use exceptions include France, Italy and the Netherlands.16

An experimental use exception has also existed in the United States common law for nearly two centuries. The doctrine is primarily invoked as protection against the "public use" bar under 35 USC §102 and against claims of patent infringement under 35 USC §271(a).17 To be used as an exception to infringement, the courts have defined experimental use as any actions performed "for amusement, to satisfy idle curiosity, or for strictly philosophical inquiry".18 The actions cannot be in the "guise of 'scientific inquiry', when that inquiry has definite, cognizable and not insubstantial commercial purposes."19 Case law emphasizing the inability of the experimental use exception to immunize use that is in any way commercial in nature has been argued to make the common law exception "essentially useless to research universities".20 However, there are other alternatives that researchers can rely on to provide some protection for experimental use, including state sovereign immunity under the Eleventh Amendment and the Hatch Waxman Act.21


New section 55.3 empowers the Governor in Council to make regulations respecting factors to be considered in determining whether a use is experimental use and circumstances in which an act is or is not experimental use. This regulation-making authority suggests that it is contemplated that there may be a need for clarifying amendments in our law as the courts start to interpret section 55.3. As no regulations have yet been made promulgated, it remains to be seen exactly what factors are open for consideration of the experimental use exception, and in what circumstances it will be applied. Judicial interpretation of the new provision, as well as corresponding regulations, will be necessary in order to elucidate the full scope of protection provided by the experimental use exception under section 55.3.

For further information, please contact a member of our firm's Patents group.


[1] Micro Chemicals Ltd. v. Smith Kline & French Inter-American Corp. (1971), 1971 CarswellNat 388, 2 C.P.R. (2d) 193 (S.C.C.). [Micro Chemicals]

[2] Ibid at 519.

[3] Dableh v. Ontario Hydro (1996), 1996 CarswellNat 2592, 68 C.P.R. (3d) 129 (F.C.A.) at para 44. [Dableh]

[4] Merck & Co. v. Apotex Inc., 2006 FCA 323, at para. 109 [Merck 2006]. See also: Merck & Co. Inc. v. Apotex Inc. 2010 CarswellNat 5009, 2010 FC 1265, 91 C.P.R. (4th) 1(F.C.) at paras. 625-637, affirmed 2011 CarswellNat 6152, 2011 FCA 363, 102 C.P.R. (4th) 321 (F.C.A.); Dableh supra note 3 at para 44.

[5] [Micro Chemicals], supra note 1; [Merck 2006] supra note 4 at para 113.

[6] FOX CANADIAN LAW OF PATENTS, ed. Donald H. MacOdrum, Fifth Edition, section 13:17 — (a) Experimental and Developmental Manufacture and Use and Non-Commercial Use [Fox]; Merck & Co., Inc. et al v. Apotex Inc., 2006 CarswellNat 1119, 2006 FC 524, 53 C.P.R. (4th) 1(F.C.) at 159-163, affirmed on this issue 2006 CarswellNat 3206, 2006 FCA 323, 55 C.P.R. (4th) 1(F.C.A.) at paras. 99-113.

[7] Teva Canada Limited v. Novartis AG, 2013 FC 141 at para 392.

[8] Micro Chemicals, supra note 1; Dableh, supra note 3.

[9] Jones v. Pearce (1832), 1 W.P.C. 121 at 125; Muntz v. Foster (1844), 2 W.P.C. 101; Frearson v. Loe (1878), 9 Ch. D. 48; Proctor v. Bayley & Son (1899), 6 R.P.C. 107.

[10] Fox, supra note 6.

[11] Jaenichen and Johann Pitz, "Research Exemption/Experimental Use in the European Union: Patents Do Not Block the Progress of Science", Cold Spring Harb Prospect Med 2015;5:a020941.

[12] Ibid at 2.

[13]Ibid at 2.

[14] Ibid at 7.

[15] Ibid at 7; Monsanto Co. v. Stauffer Chemical Co. (1985) (RPC 515).

[16] Ibid.

[17] Kris J. Kostolansky and Daniel Salgado, "Does the Experimental Use Exception in Patent Law Have a Future?", Colorado Lawyer, January 2018.

[18] Ibid, at 36.

[19] Ibid.

[20] Ibid at 37.

[21] Ibid at 38.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions